Carcinogenicity of 2',3'-dideoxycytidine in mice

Cancer Research

Volumn 56, Issue 20, 1996, Pages 4666-4672

  Rao, Ghanta N ^a   Collins, Bradley J ^a   Giles, Herschell D ^c   Heath, James E ^c   Foley, Julie F ^a   May, Richard D ^c   Buckley, Lorrene A ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b RTI INTERNATIONAL   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZALCITABINE;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CANCER RISK; CHEMICAL CARCINOGENESIS; FEMALE; GRANULOSA CELL TUMOR; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NONHUMAN; PRIORITY JOURNAL; THYMUS LYMPHOMA;

ANEMIA; ANIMALS; ANTI-HIV AGENTS; ATROPHY; BODY WEIGHT; CARCINOGENICITY TESTS; CD4-CD8 RATIO; FEMALE; LYMPHOMA, T-CELL; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; SEX FACTORS; SPECIES SPECIFICITY; THYMUS GLAND; THYMUS NEOPLASMS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; ZALCITABINE;

EID: 0029793067     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Mitsuya, H., and Broder, S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphoadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl. Acad. Sci. USA, 83: 911-915, 1986
2. Starnes, M. C, and Cheng, Y. C. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem, 262: 988-999, 1987.
3. Yarchoan, R., Thomas, R, Allain, J P., McAtee, N., Dubinsky, R., Mitsuya, H T., Safai, B., Meyers, C. E, Perno, C. F, Klecker, R W., Wills, R. J., Fischl, M A., AcNeely, M. C, Pluda, J. M., Leuther, M., Collins, J. M., and Broder, S. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with Zidovudine (AZT). Lancet, 16, 76-80, 1988.
4. Cooney, D. A., Dalal, M, Mitsuya, H, McMahon, J. B., Nadkarni, M., Balzarini, J., Broder, S, and Johns, D G. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol., 35: 2065-2068, 1986.
5. Balzarini, J., Pauwels, R., Baba, M., Herdewijn, P., De Clercq, E., Broder, S., and Johns, D. G The in vitro and in vivo antiretrovirus activity and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem. Pharmacol., 37: 897-903, 1987.
6. Klecker, R W., Collins, J M, Yarchoan, P, McAtee, N., Broder, S, and Myers, C. E. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders J. Clin. Pharmacol., 28: 837-842, 1988.
7. Kelly, A., Litterst, C. L., Roth, J. S., Vistica, D. T., Poplack, D. G, Cooney, D A., Nadkarni, M., Balis, F M., Broder, S., and Johns, D G The disposition and metabolism of 2′,3′-dideoxycytidine, an in vitro inhibitor of human T lymphotrophic virus type III infectivity in mice and monkeys Drug Metab. Dispos, 15, 595-601, 1987.
8. Gustavson, L. E., Fukuda, E. K., Rubio, F. A., and Dunton, A. W. A pilot study of the bioavailability and pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS or AIDS-related complex J. Acquired Immune Defic. Syndr., 3: 28-31, 1990.
9. Wilbourn, J., Haroun, L., Heseltine, E, Kaldor, J., Partensky, C, and Vanio, H. Response of experimental animals to human carcinogens: an analysis based upon the IARC monographs programme. Carcinogenesis (Lond), 7: 1853-1863, 1986
10. Huff, J. Chemicals causally associated with cancers in humans and laboratory animals. A perfect concordance. In: M. P. Waalakes and J. M Ward (eds.), Carcinogenesis, pp 25-37. New York: Raven Press, 1994.
11. Lindstrom, P, Harris, M, Hoberman, A. M., Dunnick, J. K., and Morrissey, R. E Developmental toxicity of orally administered 2′,3′-dideoxycytidine in mice. Teratology, 42: 131-136, 1990.
12. Luster, M I., Germolec, D R, White, K L., Jr, Fuchs, B. A., Fort, M. M., Tomaszewski, J E., Thompson, M., Blair, P. C., McCay, J A., Munson, A. E., and Rosenthal, G. J. A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematologic functions in mice: in vitro toxicity to precursor cells and microstromal environment. Toxicol Appl. Pharmacol, 101: 328-339, 1989.
13. Thompson, M B., Dunnick, J. K, Sutphin, M. E., Giles, H. D, Irwin, R. D., and Prejean, J D Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice Fundam. Appl. Toxicol, 17: 159-176, 1991.
14. Sanders, V. M, Elwell, M R., Heath, J. E., Collins, B. J., Dunnick, J. K., Rao, G. N., Prejean, D., Lindamood, C, and Irwin, R D. Induction of thymic lymphoma in mice administered the dideoxynucleoside ddC. Fundam Appl. Toxicol, 27 263-269, 1995
15. Jenkins, S. A., Copeland, N. G., Tylor, B. A., and Lee, B. K. Organization, distribution, and stability of endogenous ecotropic murine leukemia virus DNA sequences in chromosomes of Mus musculus J. Virol., 43 26-36, 1982
16. Pincus, T, Hartley, J. W., and Rowe, W. P. A major genetic locus affecting resistance to infection with murine leukemia viruses. I. Tissue culture studies of naturally occurring viruses J. Exp Med., 133: 1219-1233, 1971.
17. Tennant, R. W, Schluter, B., Yang, W. K., and Brown, A. Reciprocal inhibition of mouse leukemia virus infection by Fv-1 allele cell extracts. Proc. Natl. Acad. Sci. USA, 71: 4241-4245, 1974
18. Irons, R. D., Cathro, H. P., Stillman, W. S., Steinhagen, W. H., and Shah, R. S. Susceptibility of 1,3-butadiene-induced leukemogenesis correlates with endogenous ecotropic retroviral background in the mouse. Toxicol Appl Pharmacol., 101: 170-176, 1989.
19. Chattopadhyay, S. K., Lander, M. R., Rnads, E., and Lowry, D. R Structure of endogenous murine leukemia virus DNA in mouse genomes Proc. Natl. Acad. Sci. USA, 77: 5774-5778, 1980.
20. National Research Council Guide for the Care and Use of Laboratory Animals. Washington, DC. U.S. Government Printing Office, 1985 (NIH Publ. No. 85-23).
21. Mishell, B. B., and Shiigi, S. M. Modification and use of antibodies to label cell surface antigens. In: B B. Mishell and S. M Shiigi (eds.), Selected Methods in Cellular Immunology, pp. 287-304 San Francisco Freeman, 1980.
22. Segal, D. M., Titus, J. A., and Stephanie, D. A. Fluorescence flow cytometry in the study of lymphoid cell receptors. Methods Enzymol, 150: 478-492, 1987.
23. Parks, D. R., Herzenberg, L. A., and Herzenberg, L. A. Flow cytometry and fluorescence-activated cell sorting In: W E. Paul (ed), Fundamental Immunology, pp 781-802. New York: Raven Press, 1989.
24. Stewart, C. C. Multiparameter analysis of leukocyte by flow cytometry. Methods Cell Biol., 33: 427-450, 1990.
25. Hsu, S M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
26. Suurmeijer, A. J., and Boon, M. E. Notes on the application of microwave antigen retrieval in paraffin and plastic tissue. Eur. J. Morphol, 31: 144-150, 1993.
27. Harris, D., and Lawley, P. D. The susceptibility of inbred mice to the production of malignant thymoma by N-methyl-N-nitrosourea. Carcinogenesis (Lond.), 15: 1211-1217, 1994
28. Alterman, L. A, Crispe, I. N, and Kinnon, C Characterization of the murine heat-stable antigen: an hemolymphoid differentiation antigen defined by the J11d, M1/69 and B2A2 antibodies. Eur. J. Immunol, 20 1597-1602, 1990
29. Wenger, R H., Rochelle, J. M, Seldin, M. F., Kohler, G., and Nielsen, P. I. The heat stable antigen (mouse CD24) gene is differentially regulated, but as a housekeeping promoter J. Biol. Chem., 268: 23345-23352, 1993.
30. Roche Laboratories. HIVID product information. Physicians' Desk Reference, pp. 2121-2126. Montvale, NJ: Medical Economics Company, 1996.
31. Habteyesus, A, Nordenskjold, A., Bohman, C, and Eriksson, S. Deoxynucleotide phosphorylating enzymes in monkey and human tissues show great similarities, while mouse deoxycytidine kinase has a different substrate specificity. Biochem. Pharmacol., 42: 1829-1836, 1991.
32. Lipman, J. M., Reichert, J A., Davidovich, A., and Anderson, T. D. Species differences in nucleotide pool levels of 2′,3′-dideoxycytidine: a possible explanation of species-specific toxicity. Toxicol Appl. Pharmacol., 123: 137-143, 1993.
33. Plagemann, P., and Woffendin, C. Dideoxycytidine permeation and salvage by mouse leukemia cells and human erythrocytes. Biochem. Pharmacol., 38: 3469-3475, 1989
34. Lowe, S W. The role of p53 in apoptosis. In M. Sluyser (ed.), Apoptosis in Normal Development and Cancer, pp. 97-125. London. Taylor-Francis, 1996
35. Zhuang, S-M, Eklund, L. K, Cochran, C., Rao, G. N., Wiseman, R W., and Soderkvist, P. Allelotype analysis of 2′,3′-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice Cancer Res., 56, 3338-3343, 1996
36. Phillips, M. D, Nascimbeni, B., Tice, R. R., and Shelby, M. D. Induction of micronuclei in mouse bone marrow cells an evaluation of nucleoside analogs used in the treatment of AIDS. Environ. Mol. Mutagen., 18: 168-183, 1991